Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
NCT01422733 · University of Virginia · EARLY_PHASE1 · withdrawn · last registry update 2018-07-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study team decided not to pursue this study.” | – | Registry record, University of Virginia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-06-20Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Cyclophosphamide (NCT00408005)
- 2019-06-13Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03984448)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2018-12-12Phase 3 first posted: CMC Ambroise Paré, Hydrocortisone + Flucortac (NCT03773822)
- 2018-09-19Phase 3 first posted: SWOG Cancer Research Network, Abiraterone + Bicalutamide (NCT03678025)
- 2018-05-22Phase 3 first posted: Neurocrine UK Limited, Chronocort® + Standard Care (NCT03532022)
- 2017-08-10Results posted on the registry: Neurocrine UK Limited, Infacort + Hydrocortisone (NCT02777268)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision